Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22153077 | 0.80 | MAP3K5 (0.42) | MAP3K5HTR7 | |
| SCHEMBL21052271 | 0.78 | CDK4 (0.35) | HTR7 | |
| SCHEMBL22410742 | 0.76 | PIK3CB (0.33) | — | |
| SCHEMBL29746322 | 0.76 | PIK3CB (0.33) | — | |
| SCHEMBL21052356 | 0.74 | JAK1 (0.42) | MAP3K5 | |
| SCHEMBL25004500 | 0.74 | PDE10A (0.38) | MAP3K5 | |
| SCHEMBL18366276 | 0.73 | CYP17A1 (0.34) | CYP17A1CYP1A2 | |
| SCHEMBL15742496 | 0.73 | EGFR (0.40) | CYP17A1CYP1A2 | |
| SCHEMBL21052463 | 0.73 | HTR6 (0.50) | — | |
| SCHEMBL30692815 | 0.73 | HTR6 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | MAP3K5 3994/4885HTR7 2203/4885CYP17A1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.